The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population-论文-万方医学网

The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population

导出原文传递

翻译打印收藏纠错

作者： Beyerlin, Kassidy ^[1] ; Jimenez, Rachel ^[2] ; Zangardi, Mark ; Fell, Geoffrey G. ; Edmonds, Christine ; Johnson, Andrew ; Bossuyt, Veerle ; Specht, Michelle ; Mulvey, Therese M. ; Moy, Beverly ; Ellisen, Leif W. ; Isakoff, Steven J. ; Bardia, Aditya ; Spring, Laura M.

作者单位： Massachusetts Gen Hosp ^[1] Dana Farber Canc Inst ^[2]

关键词 Breast cancer capecitabine residual disease neoadjuvant therapy

发布时间 2022-06-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population

相似文献

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population

相似文献

相关期刊

检索历史清除